Free Trial
NASDAQ:PEPG

PepGen (PEPG) Stock Price, News & Analysis

PepGen logo
$4.29 -0.11 (-2.50%)
(As of 03:00 PM ET)

About PepGen Stock (NASDAQ:PEPG)

Key Stats

Today's Range
$4.25
$4.60
50-Day Range
$4.12
$9.76
52-Week Range
$4.00
$19.30
Volume
66,280 shs
Average Volume
121,621 shs
Market Capitalization
$139.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67
Consensus Rating
Moderate Buy

Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

PepGen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
49th Percentile Overall Score

PEPG MarketRank™: 

PepGen scored higher than 49% of companies evaluated by MarketBeat, and ranked 596th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PepGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    PepGen has only been the subject of 3 research reports in the past 90 days.

  • Read more about PepGen's stock forecast and price target.
  • Earnings Growth

    Earnings for PepGen are expected to grow in the coming year, from ($2.84) to ($2.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PepGen is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PepGen is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PepGen has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about PepGen's valuation and earnings.
  • Percentage of Shares Shorted

    3.12% of the float of PepGen has been sold short.
  • Short Interest Ratio / Days to Cover

    PepGen has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in PepGen has recently decreased by 8.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PepGen does not currently pay a dividend.

  • Dividend Growth

    PepGen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.12% of the float of PepGen has been sold short.
  • Short Interest Ratio / Days to Cover

    PepGen has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in PepGen has recently decreased by 8.01%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    PepGen has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for PepGen this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, PepGen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of PepGen is held by insiders.

  • Percentage Held by Institutions

    58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about PepGen's insider trading history.
Receive PEPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter.

PEPG Stock News Headlines

PepGen (NASDAQ:PEPG) Given New $6.00 Price Target at Bank of America
PepGen price target lowered to $6 from $10 at BofA
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
PepGen Inc. (PEPG) Receives a Buy from Stifel Nicolaus
Newpark Resources Reports Q3 2024 Financial Results
See More Headlines

PEPG Stock Analysis - Frequently Asked Questions

PepGen's stock was trading at $6.80 on January 1st, 2024. Since then, PEPG shares have decreased by 36.8% and is now trading at $4.30.
View the best growth stocks for 2024 here
.

PepGen Inc. (NASDAQ:PEPG) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.15.

PepGen (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share.

Top institutional shareholders of PepGen include Janus Henderson Group PLC (7.17%), Suvretta Capital Management LLC (5.09%), Frazier Life Sciences Management L.P. (2.16%) and Geode Capital Management LLC (1.15%). Insiders that own company stock include Ra Capital Management, LP, James G Mcarthur, Jaya Goyal, Michelle L Mellion and Niels Svenstrup.
View institutional ownership trends
.

Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that PepGen investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), Home Depot (HD) and Netflix (NFLX).

Company Calendar

Last Earnings
8/08/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/05/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PEPG
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.67
High Stock Price Target
$26.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+241.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-78,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.22 per share

Miscellaneous

Free Float
31,097,000
Market Cap
$140.18 million
Optionable
Not Optionable
Beta
1.76
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:PEPG) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners